133 related articles for article (PubMed ID: 16264349)
1. Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
Otte A; Dierckx RA
Nucl Med Commun; 2005 Dec; 26(12):1045-7. PubMed ID: 16264349
[No Abstract] [Full Text] [Related]
2. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
de Nully Brown P; Jurlander J; Lindén O; Hansen M
Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
[TBL] [Abstract][Full Text] [Related]
3. Radioimmunotherapy of non-Hodgkin's lymphoma revisited.
Goldenberg DM; Sharkey RM
J Nucl Med; 2005 Feb; 46(2):383-4. PubMed ID: 15695801
[No Abstract] [Full Text] [Related]
4. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
Hendrix CS; de Leon C; Dillman RO
Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
[TBL] [Abstract][Full Text] [Related]
5. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
6. Ibritumomab tiuxetan (Zevalin) for non-Hodgkin's lymphoma.
Med Lett Drugs Ther; 2002 Nov; 44(1144):101-2. PubMed ID: 12494494
[No Abstract] [Full Text] [Related]
7. Ongoing investigations and new uses of radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
Meredith RF
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S23-9. PubMed ID: 16979435
[TBL] [Abstract][Full Text] [Related]
8. [Indications for radioimmunotherapy for patients with non-Hodgkin's lymphoma].
Frølund UC; Hansen PB
Ugeskr Laeger; 2011 May; 173(20):1417-21. PubMed ID: 21586245
[TBL] [Abstract][Full Text] [Related]
9. [New trends in non-Hodgkin's lymphoma therapy].
Mazur G; Wróbel T; Jurczak W; Butrym A
Postepy Hig Med Dosw (Online); 2006; 60():707-21. PubMed ID: 17245320
[TBL] [Abstract][Full Text] [Related]
10. New directions in the therapeutic strategy to improve survival outcomes in patients with non-Hodgkin's lymphoma. Summary.
Bischof Delaloye A; Conti PS; Gisselbrecht C; Gregory SA
Oncologist; 2009; 14 Suppl 2():52-4. PubMed ID: 19819924
[No Abstract] [Full Text] [Related]
11. Radioimmunotherapy of Non-Hodgkin's lymphoma.
Britton KE
J Nucl Med; 2004 May; 45(5):924-5. PubMed ID: 15136647
[No Abstract] [Full Text] [Related]
12. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
Guidetti A; Carlo-Stella C; Ruella M; Miceli R; Devizzi L; Locatelli SL; Giacomini A; Testi A; Buttiglieri S; Risso A; Mariani L; Di Nicola M; Passera R; Tarella C; Gianni AM
Cancer; 2011 Nov; 117(22):5074-84. PubMed ID: 21567384
[TBL] [Abstract][Full Text] [Related]
13. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
Czuczman MS; Emmanouilides C; Darif M; Witzig TE; Gordon LI; Revell S; Vo K; Molina A
J Clin Oncol; 2007 Sep; 25(27):4285-92. PubMed ID: 17709799
[TBL] [Abstract][Full Text] [Related]
14. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
15. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.
Bennett JM; Kaminski MS; Leonard JP; Vose JM; Zelenetz AD; Knox SJ; Horning S; Press OW; Radford JA; Kroll SM; Capizzi RL
Blood; 2005 Jun; 105(12):4576-82. PubMed ID: 15731177
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma.
Bethge WA; von Harsdorf S; Bornhauser M; Federmann B; Stelljes M; Trenschel R; Baurmann H; Dittmann H; Faul C; Vogel W; Kanz L; Bunjes D
Bone Marrow Transplant; 2012 Nov; 47(11):1397-402. PubMed ID: 22504934
[TBL] [Abstract][Full Text] [Related]
17. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Gordon LI; Witzig TE; Wiseman GA; Flinn IW; Spies SS; Silverman DH; Emmanouilides C; Cripe L; Saleh M; Czuczman MS; Olejnik T; White CA; Grillo-López AJ
Semin Oncol; 2002 Feb; 29(1 Suppl 2):87-92. PubMed ID: 11842394
[TBL] [Abstract][Full Text] [Related]
18. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
Postema EJ; Oyen WJ; Boerman OC; Corstens FH
J Nucl Med; 2003 May; 44(5):853. PubMed ID: 12732690
[No Abstract] [Full Text] [Related]
19. Durable responses reported with radioimmunotherapy in low-grade non-Hodgkin's lymphoma.
Oncology (Williston Park); 2002 Mar; 16(3):304, 326. PubMed ID: 15046389
[No Abstract] [Full Text] [Related]
20. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following initial treatment with chemotherapy plus radioimmunotherapy for indolent non-Hodgkin lymphoma.
Roboz GJ; Bennett JM; Coleman M; Ritchie EK; Furman RR; Rossi A; Jhaveri K; Feldman EJ; Leonard JP
Leuk Res; 2007 Aug; 31(8):1141-4. PubMed ID: 17475326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
